TABLE 1.

Baseline Characteristics of the Crohn’s Disease Patients Enrolled in this Study (n = 123)

	Ileal Crohn’s disease	Colonic or ileocolonic Crohn’s disease	P
No. patients	40	83
Age at diagnosis mean ± sd	29.1 ± 15.5 years	21.2 ± 12.1 years	0.001
Age at baseline mean ± sd	40.3 ± 16.7 years	33.3 ± 16.6 years	0.014
Male gender, n (%)	15 (37.5%)	26 (45.6%)	0.54
Smoking habits
Current smoker, n (%)	4 (10.0%)	7 (8.4%)	0.49
Former smoker, n (%)	9 (22.5%)	12 (14.5%)
Nonsmoker, n (%)	27 (67.5%)	64 (77.1%)
Disease duration	10.8 ± 10.4 years	11.6 ± 11.8 years	0.73
Montreal classification
Location
L1, n (%)	40 (100.0%)	0 (0.0%)	< 0.0001
L2, n (%)	0 (0.0%)	28 (33.7%)	< 0.0001
L3, n (%)	0 (0.0%)	55 (66.3%)	< 0.0001
L4, n (%)	0 (0.0%)	0 (0.0%)
Behavior
B1, n (%)	8 (20.0%)	40 (48.2%)	0.011
B2, n (%)	21 (52.5%)	27 (32.5%)
B3, n (%)	11 (27.5%)	16 (19.3%)
Perianal lesions, n (%)	3 (7.5%)	29 (35.0%)	< 0.001
Prior intestinal resection, n (%)	28 (70.0%)	36 (43.4%)	0.007
HBI mean ± sd	4.5 ± 3.7	4.7 ± 3.8	0.73
HBI ≤ 4 n (%)	18 (45.0%)	40 (48.2%)	0.85
CRP (mg/L) mean ± sd	7.2 ± 11.3	9.0 ± 11.8	0.17
Fecal calprotectin (µg/g), median (IQR)	136.5 (47.4–324.3)	363.0 (83.0–813.0)	0.025
Medications at baseline
Infliximab, n (%)	7 (17.5%)	14 (16.9%)	1.00
Adalimumab, n (%)	11 (27.5%)	12 (14.5%)	0.14
Certolizumab pegol, n (%)	2 (5.0%)	3 (3.6%)	0.66
Vedolizumab, n (%)	3 (7.5%)	17 (20.5%)	0.07
Natalizumab, n (%)	0 (0.0%)	1 (1.2%)	1.00
Thiopurines, n (%)	8 (20.0%)	11 (13.3%)	0.42
Methotrexate, n (%)	3 (7.5%)	15 (18.1%)	0.17
Steroids, n (%)	8 (20.0%)	25 (30.1%)	0.28
5-ASA, n (%)	1 (2.5%)	9 (10.9%)	0.16
Endoscopy
Any lesion, n (%)	23 (57.5%)	64 (77.1%)	0.034
Any ulceration, n (%)	16 (40.0%)	44 (53.0%)	0.19
Ileum, n (%)	16 (40.0%)	20 (24.1%)	0.09
Right colon, n (%)	0 (0.0%)	11 (13.3%)	0.016
Transverse colon, n (%)	0 (0.0%)	11 (13.3%)	0.016
Left/sigmoid colon, n (%)	0 (0.0%)	24 (28.9%)	< 0.0001
Rectum, n (%)	0 (0.0%)	22 (26.5%)	< 0.0001